<DOC>
	<DOCNO>NCT00561262</DOCNO>
	<brief_summary>RATIONALE : High-intensity focus ultrasound energy may able kill tumor cell heat without affect normal tissue . PURPOSE : This phase II trial study well high-intensity focus ultrasound ablation therapy work treat patient localized prostate cancer .</brief_summary>
	<brief_title>High-Intensity Focused Ultrasound Therapy Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine patient acceptability , feasibility , side-effect profile evaluate record adverse event . - To determine patient acceptability , feasibility , side-effect profile evaluate urinary symptom erectile function study stage 1 ( verification ) , study stage 2 ( treatment ) , follow-up visit . Secondary - To determine effectiveness therapy post-treatment transrectal ultrasound-guided biopsy 6 month evidence biochemical failure . - To determine effectiveness therapy post-treatment MRI evaluate area necrosis presence residual tissue . - To determine effectiveness therapy measurement prostate-specific antigen ( PSA ) follow-up visit measurement time PSA nadir . - To determine effectiveness therapy record need secondary adjuvant treatment follow therapy . OUTLINE : Patients undergo hemiablation use high-intensity focus ultrasound side prostate cancer 5 mm contralateral side ensure adequacy . Patients complete questionnaire periodically study assess urinary symptom erectile dysfunction . These include International Index Erectile Function-15 [ IIEF-15 ] ; International Prostate Symptom Score [ IPSS ] IPSS-QoL ; Functional Assessment Cancer Therapy - Prostate ( FACT-P ) ; Continence Questionnaire . After completion study treatment , patient follow 2-7 day , 7-14 day , 1 , 3 , 6 , 9 , 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate , meet follow criterion : Gleason score ≤ 7 ( pattern 3+4 4+3 less acceptable ) Cancer prostateconfined Cancer confine one lobe define transrectal ultrasound ( TRUS ) biopsy Serum prostatespecific antigen ( PSA ) ≤ 15 ng/mL Prostate volume ≤ 40 cc OR AP length prostate &lt; 4 cm Unilateral prostate adenocarcinoma must verify stage 1 trial unless patient multisequence MRI transperineal template biopsy outside trial similar procedure protocols trial No evidence metastatic disease No intraprostatic calcification ≥ 10 mm size cancerpositive side prostate PATIENT CHARACTERISTICS : Life expectancy ≥ 5 year No latex allergies No American Society Anesthesiology surgical risk score III IV No contraindication MRI scanning ( e.g. , severe claustrophobia , permanent cardiac pacemaker , metallic implant likely contribute significant artefact image ) Must fit general anesthesia regional anesthesia assess consultant anesthetist PRIOR CONCURRENT THERAPY : More 6 month since prior androgen suppression therapy No prior radiotherapy prostate cancer No prior chemotherapy prostate cancer No prior significant rectal surgery prevent insertion transrectal probe No prior transurethral resection prostate laser prostatectomy No prior highintensity focus ultrasound , cryosurgery , thermal , microwave therapy prostate</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>